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The authors note that Fig. 4 appeared incorrectly. The corrected figure and its legend appear below. These errors do not affect the conclusions of the article. Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disorder caused by a polyglutamine repeat (polyQ) expansion within the human androgen receptor (AR). Unlike other neurodegenerative diseases caused by abnormal polyQ expansion, the onset of SBMA depends on androgen binding to mutant human polyQ-AR proteins. This is also observed in Drosophila eyes ectopically expressing the polyQ-AR mutants. We have genetically screened mediators of androgen-induced neurodegeneration caused by polyQ-AR mutants in Drosophila eyes. We identified Rbf (Retinoblastoma-family protein), the Drosophila homologue of human Rb (Retinoblastoma protein), as a neuroprotective factor. Androgen-dependent association of Rbf or Rb with AR was remarkably potentiated by aberrant polyQ expansion. Such potentiated Rb association appeared to attenuate recruitment of histone deacetyltransferase 1 (HDAC1), a corepressor of E2F function. Either overexpression of Rbf or E2F deficiency in fly eyes reduced the neurotoxicity of the polyQ-AR mutants. Induction of E2F function by polyQ-AR-bound androgen was suppressed by Rb in human neuroblastoma cells. We conclude that abnormal expansion of polyQ may potentiate innate androgen-dependent association of AR with Rb. This appears to lead to androgen-dependent onset of SBMA through aberrant E2F transactivation caused by suppressed histone deacetylation.
transcriptional regulation ͉ neurodegenerative disease ͉ retinoblastoma protein X -chromosome-linked spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a degenerative motor neuron disorder caused by CAG repeat [encoding polyglutamine (polyQ)] expansions in the first exon of the human androgen receptor (AR) gene (1) . Characteristic movement disorders, neuropsychiatric symptoms, and late onset of neurodegeneration are well described in SBMA patients carrying AR mutations coding for abnormally expanded polyQ repeats (polyQ-AR) (2) . There are similarities to other congenital neuronal diseases induced by polyQ repeat expansions such as Huntington's disease and spinocerebellar ataxia atrophy (3). Neurodegeneration resulting from polyQ-AR has also been experimentally demonstrated in mice and flies (4, 5) . SBMA is different from other neurodegenerative diseases in that this disease is male-specific in mammals, presumably due to the physiologically sufficient levels of androgens required to activate the neurodegenerative response of polyQ-AR mutants (6, 7) . As is the case for other polyglutamine diseases, the molecular basis of SBMA neuropathology remains elusive. However, because of the androgen dependency of SBMA development, the neuropathology is considered innate to AR function.
Most androgen actions are mediated through the AR, a ligand-inducible transcription factor that belongs to the nuclear hormone receptor superfamily (8) . In the absence of ligand, AR is located primarily in the cytoplasm as an inactive complex with heat shock proteins. Upon androgen binding, AR undergoes conformational change, translocates into the nucleus, and recruits coactivator complexes for transactivation through direct DNA binding to androgen response elements (AREs) in AR target gene promoters (9, 10) . As observed in wild-type AR, polyQ-AR mutants reportedly translocate into the nucleus and recruit coactivator complexes to the AREs in a liganddependent manner (11) .
Previously, we established an androgen-dependent SBMA Drosophila model by ectopically expressing human polyQ-AR mutants in eye discs (4) . Androgen-induced conformational change of polyQ-ARs and their translocation into the nucleus appeared to dramatically increase cytotoxicity of the polyQ-AR, leading to neuronal cell death. Because the neurodegenerative abnormalities of this SBMA model were indistinguishable from those in flies expressing other mutant polyQ-expanded repeats that do not require androgen, diseases mediated by polyQexpanded repeats appear to share common and evolutionarily conserved neurodegenerative mechanisms (3, 12, 13) .
To identify factors required for androgen-induced neurodegeneration, we performed a genetic screen crossing polyQ-AR transgenic flies with gmr-GAL4-driven overexpression lines. We identified retinoblastoma-family protein (Rbf ), the Drosophila homologue of human retinoblastoma protein (Rb), to be a repressive factor for androgen-induced neurodegeneration caused by polyQ-AR mutants. Potentiated association of Rb with AR by the aberrant polyQ expansion was inhibitory for recruitment of HDAC1 corepressing E2F function. E2f deficiency partially rescued the neurodegenerative rough eye phenotype in the polyQ-AR mutants. PolyQ-AR mutants, but not the wild-type AR, stimulated E2F-mediated transactivation. Thus, abnormal polyQ-AR seems to have impaired Rb transrepressive function. The resultant E2F hyperactivation may induce the androgen-dependent onset of the SBMA disorders.
Results

Rbf Overexpression Rescues PolyQ-AR-Induced Neurodegeneration.
We reported that neurodegeneration induced by the full-length human polyQ-AR mutant [AR(Q52)] was ligand-dependent, but the N-terminal domain of the polyQ-AR mutant [AR(Q52 AF-1)] was constitutively and sufficiently potent to induce neurodegeneration as a rough eye phenotype ( Fig. 1A and B) (4). This ligand-independent neurodegeneration by AR(Q52 AF-1) is advantageous for genetic screening to identify modifiers of polyQ-AR mutant-dependent neurodegeneration. To understand the molecular basis of polyQ-AR-induced neurodegeneration, we carried out genetic screening for modifiers of eye degradation. We crossed GS lines (which misexpressed unknown genes driven by the GAL4 protein) with UAS-AR (Q52 AF-1) lines driven by gmr-GAL4. With gmr-GAL4, gene expression could be specifically targeted to the eye. After screening Ϸ2,000 fly strains, several candidate genes capable of modifying the rough eye phenotype were identified. To verify reproducibility of the phenotype, putative modifiers selected in the initial screen were further tested by crossing with different independent strains expressing AR(Q52) in the presence of an active androgen [dihydrotestosterone (DHT)]. One of the candidate lines, GS-5173, was found to rescue neurodegeneration by AR(Q52 AF-1) and androgen (DHT)-bound AR(Q52) (Fig. 1B) .
With the Drosophila Gene Search Project (DGSP) database, analysis of genomic sequences downstream of the P element in the GS-5173 line led to identification of the Rbf gene. Thus, the gmr-GAL4-driven GS-5173 line was expected to be an Rbf overexpression mutant. We verified Rbf function by crossing a UAS-AR(Q52 AF-1) line with an Rbf overexpression line, gmrRbf. Rbf overexpression clearly prevented the rough eye phenotype induced by either AR(Q52 AF-1) or AR(Q52) in the presence of DHT (Fig. 1B) .
To determine the specificity of Rbf as a modifier of the neurodegenerative phenotype, Rbf overexpression lines were then crossed with a strain expressing the isolated polyQ127 repeat alone, the UAS-polyQ-127 line or the UAS-polyQ-ataxin3 line (SCA3trQ78 line), a Drosophila model of spinocerebellar ataxia type 3 (12) . Notably, Rbf overexpression was unable to rescue neurodegeneration by either polyQ127 or SCA3tr-Q78 ( Fig. 1 C and D) . These results suggested that Rbf genetically and selectively interacts with polyQ-AR mutants in the adjacent regions and not through the polyQ repeats themselves in the AR mutants.
Androgens Stimulate the Interaction of PolyQ-AR Mutants with Rb.
For detailed analysis of the phenotypic effects of overexpression of Rbf, we tested possible interactions between AR and endogenous Rb in human embryonic kidney 293T cells transfected with either AR(wt) or AR(Q52) expression constructs. By co-immunoprecipitation (Co-IP) and Western blot (WB) assays, Rb was shown to weakly interact with AR(wt). Interaction appeared to depended on binding of DHT but not hydroxyflutamide (HF), the antagonist for AR(wt) (Fig. 2A) . In contrast, the interaction of AR(Q52) with Rb was remarkably pronounced with both DHT and HF. Surprisingly, HF served as an agonist in the association. This observation supports our previous findings that HF serves as an agonist for polyQ-AR-dependent neurodegeneration (4) . To examine whether the potential association of AR with Rb was mediated through the expanded polyQ repeats, a similar Co-IP experiment was performed in 293T cells expressing ataxin-3, which contains a polyQ60 repeat similar to that of the polyQ-AR mutants. Consistent with the inability of Rb to rescue the polyQ-expanded ataxin-3-induced neurodegeneration phenotype (Fig. 1D) , no association of Rb with ataxin-3(Q60) was detected in the Co-IP assay with anti-Rb antibodies (Fig. 2B) . These results support our hypothesis that Rb interacts selectively with polyQ-AR mutants.
We then performed GST pull-down assays to determine whether the functional interaction of the polyQ-AR mutant with Rb is direct, using recombinant proteins consisting of AR deletion mutants and GST-fused Rb. Rb physically interacted with the AR A/B domain containing expanded polyQ [AR(Q52) A/B] but not with its wild-type [AR(wt) A/B] (Fig. 2C) . The AR C/D/E/F mutant reportedly associates with Rb (14) . Because the AR C domain bears a ''LXCXE''-like motif (LICGDE), a consensus Rb-contacting motif (15) , its impact was then tested with an AR point mutant (LIAGDE). This mutation in the full-length AR [AR(wt) C562A] resulted in loss of the Rb association (Fig. 2D) . However, even in this mutant, the polyQ-AR mutant [AR(Q52) C562A] was still capable of interacting with Rb. Although the Rb associations with AR mutants were weak in the GST pull-down assay, the associations were more clearly ligand-dependent in a Co-IP experiment in 293T cells (Fig. S1B ). This discrepancy in ligand dependency between GST pull-down and Co-IP experiments may be due to nuclear translocation of liganded ARs in intact cells. Taken together, these results suggest that the aberrantly potentiated association of polyQ-AR and Rb is mediated not only through the C domain but also through the A/B domain of the polyQ-AR mutants.
At this point, we mapped the Rb-interacting domains for ARs. The 3 tested Rb domains seemed to weakly associate with AR(wt), whereas the polyQ expansion [AR(Q52)] significantly potentiated the association with the Rb A/B pocket and C mutants in the GST pull-down assay (Fig. 2E) . Similar results were also obtained in a Co-IP experiment using 293T cells (Fig.  S1C) . Because the Rb A/B pocket domain is known as the E2F binding pocket repressing the transactivation function of E2F, we assumed that the abnormal polyQ expansion in AR modulates the E2F function via its association with the Rb A/B pocket.
Because Rb reportedly coactivates the transactivation function of androgen-bound AR (14, 16), we then tested whether Rb serves as an AR coactivator for the polyQ-AR mutant. No functional differences in the coactivation by Rb (Fig. 2F) or E2F1 (Fig. S1D) were observed in AR(wt) or AR(Q52) in the human neuroblastoma cell line, SH-SY5Y.
PolyQ-AR Counteracts Rb for E2F Repression. The Rb protein negatively regulates the G 1 /S transition by repressing the transcriptional activity of the E2F transcription factors. Rbf also represses dE2f-dependent transcription and suppresses the phenotype generated by ectopic expression of dE2f and dDp in the developing Drosophila eye (17) (Fig. 3A) . Because Rbf overexpression prevents polyQ-AR-induced neurodegeneration in the fly eye similarly to dE2f/dDp1-induced neurodegeneration, we reasoned that E2F transactivation may mediate polyQ-AR-induced neurodegeneration. To test this idea, we crossed the AR(Q52 AF-1) line with dE2f-deficient mutant lines. In 2 independent Drosophila mutant lines deficient in dE2f, E2f 07172 and E2f i2 , the action of AR(Q52 AF-1) in the rough eye was partially reduced when compared with that in the control fly (Fig. 3B) . Partial rescue of the rough eye phenotype by the dE2f mutant was also prevented by Rbf overexpression (Fig. 3C) . These results indicate that dE2f transactivation is enhanced in the Drosophila eye model of SBMA.
Next, we examined whether polyQ-AR influences the transactivation function of E2F1 in the human neuroblastoma cell line SH-SY5Y. An E2F-dependent reporter plasmid with a cassette of 6 E2F binding sites derived from the E2F1 gene promoter was cotransfected with expression vectors for AR, Rb, or both. Considerably weaker transcriptional activation of endogenous E2F1 was observed with AR(wt) activated by DHT (Fig. 3D) . However, AR(Q52) activated by DHT significantly enhanced E2F1 transcriptional activity (Fig. 3D) . The AR antagonist, HF, also enhanced E2F1 transcriptional activity. Furthermore, coexpression of Rb abrogated the enhancement of E2F1 transactivation by AR(Q52) (Fig. 3D) .
We then studied the molecular basis of the functional association of the polyQ-AR mutant with E2F1. With Co-IP with anti-E2F1 antibody (Fig. 3E) , we observed DHT-induced association of endogeneous E2F1 with AR(Q52). The association was undetectable when Rb was knocked down by siRNA (Fig. 3E and Fig. S2 A) . Thus, it appears that Rb bridges E2F1 to the AR(Q52) mutant. This idea was further confirmed by the finding that the AR(Q52) mutant was not coimmunoprecipitated with an E2F1 mutant (E2F1‚C) lacking its Rb-interacting domain (Fig. S2 B and C) .
Because the polyQ-AR mutant inhibited the transrepressive function of RB for E2F1, we reasoned that the polyQ-AR mutant might attenuate recruitment of the Rb corepressor, HDAC1, through association of the Rb transrepressive domain (A/B pocket domain). We found that HDAC1's association with Rb was unaffected by AR(wt)-bound DHT. However, binding of DHT to AR(Q52) indeed induced HDAC1 dissociation (Fig. 3F) .
Activation of E2F Target Gene Expression by PolyQ-AR Mutants. Next, we asked whether the expression of polyQ-AR indeed leads to expression of endogenous E2F1 target genes, both in vivo and in vitro. In the UAS-AR(Q52) fly eye, RT-PCR analysis revealed that the Drosophila dE2f target gene Drosophila PCNA (dPCNA) was up-regulated severalfold (Fig. 4A) . Likewise, transient expression of AR(Q52) in human SH-SY5Y cells led to upregulation of Cyclin E gene expression (Fig. 4B) . However, such up-regulation of E2F1 target genes was not obvious for AR(wt). Consistent with the reporter gene expression assay data, overexpression of both Rbf in Drosophila eyes and Rb in human neuroblastoma cells abrogated activation of the E2F target genes by the polyQ-AR mutant.
To explore the molecular basis of polyQ-AR function in E2F target gene expression, the recruitment of ARs to the E2F target gene promoters was tested by chromatin immunoprecipitation (ChIP) analysis. DHT-induced recruitment of AR(Q52) to E2F binding sites was observed at the dPCNA gene promoters, together with the expected dissociation of Drosophila HDAC1 (Rpd3) and hyperacetylation of histone H3, although Rbf association appeared unchanged (Fig. 4C) . Similarly, DHT-bound AR(Q52) was recruited to the E2F binding site of the human Cyclin E gene promoter with dissociation of HDAC1 and hyperacetylation of histone H3 in SH-SY5Y cells (Fig. 4D) . It is notable that, unlike AR(Q52), AR(wt) did not associate with the Cyclin E gene promoter. Rb overexpression inhibited the association of AR(Q52) with the E2F1 target gene promoter (Fig. 4D) .
Discussion
In this report, we used genetic screening for neuroprotective factors for the neurodegenerative (rough eye) phenotype in a Drosophila model of SBMA and identified Rbf/Rb as a candidate (Fig. 1) . The retinoblastoma tumor suppressor Rb and related factors, such as mammalian p107 and p130 or Drosophila Rbf, are negative regulators of cell proliferation. Rb functions at major G 1 checkpoints, thereby inhibiting S-phase entry and progression. They also promote terminal differentiation by inducing both cell-cycle exit and tissue-specific gene expression (18, 19) .
Consistent with the neuroprotective action of Rbf, we found that expansion of polyQ repeats in AR mutants augmented the physical association of Rbf and Rb with the polyQ-AR protein.
Because Rb was unable to counteract the neurodegenerative activity of the expanded polyQ repeat on its own (Fig. 1C) , Rb/Rbf thus appears to be a selective neuroprotective factor for SBMA among hereditary polyglutamine diseases. We attribute the selective Rb/Rbf activity to its enhanced association with polyQ-AR mutants. This idea is consistent with the recent findings that abnormal polyQ expansion in spinocerebellar ataxia type 1 protein potentiates native protein interactions, thus leading to neuropathology (20, 21) .
It is widely accepted that Rb and related factors function through their effects on the transcription of genes regulated by the E2F proteins. E2F binding sites are found in the promoters of many genes essential for cell-cycle progression and cell proliferation. Most Rb regulatory functions are associated with the repressor activities of Rb/E2F complexes located on the promoters of cell-cycle regulatory genes such as Cyclin E and the E2F transcription factor (22) (23) (24) . Moreover, many E2F1 target genes regulate apoptosis, development, and differentiation. Overexpression of E2F1 in mammalian cells results in the induction of apoptosis (25) (26) (27) . Similarly, ectopic expression of Drosophila E2f induces apoptosis in imaginal discs and, if expressed in the eye discs, causes the rough eye phenotype (28) . Significantly, in our genetic analysis, E2f-deficient Drosophila mutants partially reversed the polyQ-AR-induced rough eye phenotype (Fig. 3B) . Expression of Rb abrogated E2F1 transactivation by polyQ-AR (Fig. 3D) . The reporter expression assay data were further confirmed by observations of polyQ-ARinduced expression of endogenous E2F target genes in Drosophila eye disc and cultured mammalian cells (Fig. 4 A and B) . These findings suggest that polyQ-AR activates endogenous E2F1 proteins in neuronal cells in a ligand-dependent manner. Although it was reported that Rb coactivates AR through its physical association (14, 16) , no association of the other 8 polyQ-expanded proteins with Rb have been mentioned. In the present study, we also could not detect the interaction of polyQ-ataxin-3 with Rb (Fig. 2B) . Thus, we presume that, among the polyQ-expanded proteins, only polyQ-AR selectively enhances E2F1 transactivation via Rb.
The transrepression function of Rb/Rbf for E2F1 requires HDAC1 to deacetylate histone for chromatin inactivation (18) . As expected, wild-type AR did not affect the function of Rb or E2F1. However, supporting our in vitro observations that the polyQ-AR mutant competed with HDAC1 in Rb associ- ation, the polyQ-AR mutant was an overt coactivator for E2F1. Thus, it appears that impaired HDAC1 recruitment to Rb induced by liganded polyQ-AR mutants causes hyperfunction of E2Fs (see Fig. S3 ), leading to androgen-induced development of SBMA.
Derepression of the Rb/E2F1 transcriptional complex, or in other words aberrant activation of E2F1, has been implicated in diverse human neurological disorders including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (29) (30) (31) . Thus, albeit by different mechanisms, diverse neurodegenerative agents appear to share a significant common trait (i.e., E2F activation).
In conclusion, we have presented evidence that abnormal polyQ expansion in AR leads to aberrant E2F1 activation presumably through suppression of Rb function by androgeninduced physical interaction of Rb with polyQ-AR mutants. Given the roles of E2F protein family members in cellular toxicity, aberrant activation of E2F factors appears to underlie the androgen-dependent neurodegenerative function of polyQ-AR mutants in the development of SBMA. Our data imply that disabling E2Fs or Rb reactivation might provide an approach to the prevention of neurodegeneration in SBMA.
Experimental Procedures
Please see SI Text for the following detailed methods: fly stocks, plasmids, immunoprecipitation, cell culture and transfection; GST pull-down assays, RT-PCR, and chromatin immunoprecipitation. 
